Gilead: HIV Franchise Woes Highlight Cancer Follies
Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...
Zacks Investment Research on MSN21h
Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note
Gilead Sciences (GILD) ended the recent trading session at $111.88, demonstrating a +0.54% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of ...
moneycontrol.com12h
Gilead Sciences
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...